From Big Pharma to little Tessera, Michael Severino rewrites his next chapter as CEO of Flagship biotechnews2022-06-01T16:37:33+00:00June 1st, 2022|FierceBiotech|
Amgen’s heart drug reduces cardiovascular disease risk factor in phase 2 trialnews2022-06-01T15:02:06+00:00June 1st, 2022|FierceBiotech|
Tech-Enabled Trials Don’t Have to Mean Loss of Human Connectionnews2022-06-01T15:00:52+00:00June 1st, 2022|FierceBiotech|
BioMarin’s hemophilia A gene therapy further delayed amid new FDA questionsnews2022-06-01T14:06:44+00:00June 1st, 2022|FierceBiotech|
Sanofi’s Hemlibra rival gets step closer to approval with FDA breakthrough tagnews2022-06-01T13:55:05+00:00June 1st, 2022|FierceBiotech|
SKYLARK sings: Sage, Biogen hatch positive phase 3 data in postpartum depressionnews2022-06-01T11:39:08+00:00June 1st, 2022|FierceBiotech|
GO! Astellas picks up partner in convertibleCAR for backloaded $780M antibody projectnews2022-06-01T10:43:44+00:00June 1st, 2022|FierceBiotech|
Bristol Myers Squibb, with new positive lupus data in hand, readies TYK2 inhibitor for final testnews2022-06-01T09:19:57+00:00June 1st, 2022|FierceBiotech|
After Axsome’s migraine med rejection, phase 3 data keep hope alive for depression drugnews2022-05-31T14:44:33+00:00May 31st, 2022|FierceBiotech|
After Axsome’s migraine med rejection, phase 3 data keeps hope alive for depression drugnews2022-05-31T14:44:33+00:00May 31st, 2022|FierceBiotech|
